The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Sotorasib Tablets Market Across 2026–2030?
The sotorasib tablets market has seen substantial growth in recent years. Its valuation is expected to ascend from $1.92 billion in 2025 to $2.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.3%. The market’s expansion historically stems from an increase in the diagnosis of non-small cell lung cancer, advancements made in KRAS mutation research, regulatory approvals granted for targeted oncology drugs, an expansion of molecular diagnostic capabilities, and a rise in oncology clinical trials.
The sotorasib tablets market size is projected to experience substantial expansion over the coming years, reaching $3.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.0%. This growth during the forecast period is propelled by factors such as the accelerated development of next-generation kras inhibitors, an increase in combination therapy strategies, the extension of targeted treatments to encompass more cancer indications, the wider application of real-world evidence studies, and the growing uptake of oncology precision medicine. Key developments anticipated in this period encompass the increasing integration of kras g12c inhibitor therapies, an intensified focus on targeted therapies for lung cancer, the broader utilization of oral oncology drugs, the broadening scope of companion diagnostic testing, and improved surveillance of resistance mechanisms.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28336&type=smp
What Primary Drivers Are Shaping The Development Of The Sotorasib Tablets Market?
The growing incidence of cancer is anticipated to propel the expansion of the sotorasib tablets market moving forward. Cancer involves a group of conditions where abnormal cells proliferate uncontrollably, invade surrounding tissues, and can metastasize to other body parts. The increasing occurrence of cancer is linked to an aging demographic, given that advanced age constitutes the most significant risk factor for developing the majority of cancer types, with most cases affecting individuals over 65 years old. Sotorasib tablets function by specifically and irreversibly targeting the KRAS G12C mutation, permanently deactivating the mutated protein to prevent uncontrolled cell growth in patients with advanced solid tumors, particularly non-small cell lung cancer. For instance, in February 2024, the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, projected over 35 million new cancer cases in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Consequently, the rising prevalence of cancer is fueling the growth of the sotorasib tablets market. The increasing number of older adults is expected to fuel the expansion of the sotorasib tablets market in the future. The geriatric population refers to the segment of older individuals, generally those aged 65 years and above, who may experience various physiological, psychological, and social changes associated with aging. This rise in the geriatric population is primarily attributable to extended life expectancy, as advancements in healthcare, improved nutrition, and better living conditions enable more people to live longer, thereby increasing the proportion of older adults in society. Sotorasib tablets assist the geriatric population by specifically targeting KRAS G12C-mutated cancers, providing a precise therapeutic option that addresses age-related vulnerabilities and enhances treatment outcomes for older individuals. For instance, in July 2024, according to the UK Parliament’s House of Commons Library, a UK-based government administration, there were 12.7 million people aged 65 or older in the UK in 2022, constituting 19% of the total population. This figure is projected to climb to 22.1 million by 2072, making up 27% of the population. Hence, the growing geriatric population is driving the growth of the sotorasib tablets market.
What Segmentation Levels Are Considered In The Sotorasib Tablets Market?
The sotorasib tablets market covered in this report is segmented –
1) By Dosage Form: 40 Milligrams (Mg) Tablets, 120 Milligrams (Mg) Tablets, 240 Milligrams (Mg) Tablets, Other Dosage Forms
2) By Patient Demographics: Adolescents, Adult, Senior Adults
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Non-Small Cell Lung Cancer, Colorectal Cancer, Other Applications
5) By End-User: Hospitals, Oncology Centers, Clinics, Other End-Users
What Trends Are Projected To Affect The Sotorasib Tablets Market?
Leading companies in the sotorasib tablets market are concentrating on developing innovative treatment approaches, such as combination therapies, to enhance efficacy and overcome resistance. These combination treatments involve the concurrent use of two or more drugs to target cancer through multiple mechanisms simultaneously, helping to boost treatment effectiveness, combat or postpone drug resistance, decrease the likelihood of cancer recurrence, and improve overall patient outcomes and quality of life. For example, in January 2025, Amgen Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) approval for sotorasib in combination with panitumumab. This approval was for the treatment of adult patients with KRAS G12C–mutated metastatic colorectal cancer (mCRC) who had previously undergone standard chemotherapy. The approval was founded on the results of the Phase 3 CodeBreaK 300 study, which indicated that the combination more than doubled progression-free survival compared to the investigator’s choice of standard-of-care therapy, thereby offering a significant new option for patients with this difficult-to-treat cancer. Sotorasib functions as a first-in-class, oral KRAS G12C inhibitor by selectively targeting and locking the mutant KRAS protein in its inactive state, consequently blocking cancer cell growth and signaling pathways driven by this mutation.
Which Leading Firms Are Contributing To The Growth Of The Sotorasib Tablets Market?
Major companies operating in the sotorasib tablets market are Amgen Inc.
Read the full sotorasib tablets market report here:
https://www.thebusinessresearchcompany.com/report/sotorasib-tablets-global-market-report
How Does The Sotorasib Tablets Market Perform Across Major Global Regions?
North America was the largest region in the sotorasib tablets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotorasib tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Sotorasib Tablets Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28336&type=smp
Browse Through More Reports Similar to the Global Sotorasib Tablets Market 2026, By The Business Research Company
Tablets Market Report 2026
https://www.thebusinessresearchcompany.com/report/tablets-global-market-report
Ashwagandha Extract Market Report 2026
https://www.thebusinessresearchcompany.com/report/ashwagandha-extract-global-market-report
Cholinergic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model